Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBW 2992 after EGFR-TKI failure in advanced non-small cell lung cancer
NL-OMON36544Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of afatinib and paclitaxel in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Overall survival. Started Nov 2010; status: active, not recruiting.
02
Drugs
afatinibpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36544.